1. Market Research
  2. > Pathology
29 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Zydelig 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Zydelig through reportable promotional activity in 2018 and how does this compare to its peer set in the Chronic Lymphocytic Leukemia, Follicular Lymphoma, Non-Hodgkin’s Lymphoma, an

  • Cancer
  • Lymphoma
  • Pathology
  • United States

Adcetris 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Adcetris through reportable promotional activity in 2018 and how does this compare to its peer set in the Anaplastic Large Cell Lymphoma, Hodgkin Lymphoma, and Non-Hodgkin’s Lymphoma

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Rituxan Hycela 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 21 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Rituxan Hycela through reportable promotional activity in 2018 and how does this compare to its peer set in the Chronic Lymphocytic Leukemia, Follicular Lymphoma, and Non-Hodgkin’s L

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Pathology
  • United States

Calquence 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Calquence through reportable promotional activity in 2018 and how does this compare to its peer set in the Mantle Cell Lymphoma and Non-Hodgkin’s Lymphoma markets?

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Rituxan 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 25 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Rituxan through reportable promotional activity in 2018 and how does this compare to its peer set in the Chronic Lymphocytic Leukemia, Follicular Lymphoma, Microscopic Polyangiitis,

  • Cancer
  • Health Care Provider
  • Health Services
  • Lymphoma
  • United States

Keytruda 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 31 pages

Lymphoma markets?

  • Cancer
  • Health Care Provider
  • Lymphoma
  • Pathology
  • United States

Imbruvica 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Imbruvica through reportable promotional activity in 2018 and how does this compare to its peer set in the Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Non-Hodgkin’s Lymphoma,

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Folotyn 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 26 pages

Folotyn 2018 U. S.

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Revlimid 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 25 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Revlimid through reportable promotional activity in 2018 and how does this compare to its peer set in the Mantle Cell Lymphoma and Multiple Myeloma markets?

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Yescarta 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

Yescarta 2018 U. S.

  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Kymriah 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 26 pages

Kymriah 2018 U. S.

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Bendeka 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

Bendeka 2018 U. S.

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Aliqopa 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

Aliqopa 2018 U. S.

  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Zevalin 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 24 pages

Zevalin 2018 U. S.

  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Venclexta 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 21 pages

Venclexta 2018 U. S.

  • Cancer
  • Leukemia
  • Lymphoma
  • Pathology
  • United States

Opdivo 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 25 pages

Opdivo 2018 U. S.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • United States

Gazyva 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 21 pages

Gazyva 2018 U. S.

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Beleodaq 2017 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2018
  • 24 pages

Beleodaq 2017 U. S.

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Treanda 2017 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2018
  • 19 pages

Treanda 2017 U. S.

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States

Intron A 2016 U.S. Promotional Audit Report

  • $ 1650
  • July 2017
  • 21 pages

Promotional Audit Report The ## Key Questions Addressed by this Report: • How many physicians were reached by Intron A through personal promotion in 2016 and how does this compare to its peer set in the Follicular Lymphoma, Hairy Cell Lymphoma, and Melanoma markets?

  • Cancer
  • General Medicine And Specialty Medicine
  • Lymphoma
  • Oncology
  • United States
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on